PTC Misses Phase III In Friedrich Ataxia, But Isn’t Giving Up
Company Ends Gene Therapy R&D, Cuts Headcount
Pointing to data showing benefit in patients who completed 72 weeks of therapy, PTC thinks vatiquinone still could be viable for pediatric FA patients. Restructuring won’t affect Upstaza.
